Found: 76
Select item for more details and to access through your institution.
Mutational and cytogenetic analyses of 188 CLL patients with trisomy 12: A retrospective study from the French Innovative Leukemia Organization (FILO) working group.
- Published in:
- Genes, Chromosomes & Cancer, 2018, v. 57, n. 11, p. 533, doi. 10.1002/gcc.22650
- By:
- Publication type:
- Article
Hybrid simultaneous whole-body 2-[<sup>18</sup>F]FDG-PET/MRI imaging in newly diagnosed multiple myeloma: first diagnostic performance and clinical added value results.
- Published in:
- European Radiology, 2023, v. 33, n. 9, p. 6438, doi. 10.1007/s00330-023-09593-1
- By:
- Publication type:
- Article
Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 9, p. 1746, doi. 10.1002/ajh.27382
- By:
- Publication type:
- Article
Phase I study of zoledronic acid combined with escalated doses of interleukine‐2 for early in vivo generation of Vγ9Vδ2 T‐cells after haploidentical stem cell transplant with posttransplant cyclophosphamide.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 3, p. 350, doi. 10.1002/ajh.27191
- By:
- Publication type:
- Article
Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 4, p. 418, doi. 10.1002/ajh.26083
- By:
- Publication type:
- Article
Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies.
- Published in:
- Cells (2073-4409), 2020, v. 9, n. 3, p. 717, doi. 10.3390/cells9030717
- By:
- Publication type:
- Article
Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
- Published in:
- Cell Death & Disease, 2020, v. 11, n. 5, p. 1, doi. 10.1038/s41419-020-2505-1
- By:
- Publication type:
- Article
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real‐world: The retrospective IMAGE study.
- Published in:
- European Journal of Haematology, 2024, v. 113, n. 3, p. 290, doi. 10.1111/ejh.14225
- By:
- Publication type:
- Article
Prognostic impact of early‐versus‐late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT.
- Published in:
- European Journal of Haematology, 2021, v. 106, n. 5, p. 708, doi. 10.1111/ejh.13602
- By:
- Publication type:
- Article
Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?
- Published in:
- European Journal of Haematology, 2017, v. 99, n. 1, p. 60, doi. 10.1111/ejh.12891
- By:
- Publication type:
- Article
New Data on Subcutaneous Bortezomib.
- Published in:
- Acta Haematologica, 2014, v. 133, n. 1, p. 26, doi. 10.1159/000362639
- By:
- Publication type:
- Article
Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma.
- Published in:
- International Journal of Molecular Sciences, 2020, v. 21, n. 15, p. 5406, doi. 10.3390/ijms21155406
- By:
- Publication type:
- Article
PET Imaging for Initial Staging and Therapy Assessment in Multiple Myeloma Patients.
- Published in:
- International Journal of Molecular Sciences, 2017, v. 18, n. 2, p. 445, doi. 10.3390/ijms18020445
- By:
- Publication type:
- Article
P-221: Evolution of Dara-based regimen use along treatment lines from 2016 to 2019: a real-life study based on the French national claim database.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S161, doi. 10.1016/S2152-2650(21)02348-X
- By:
- Publication type:
- Article
P-210: Oral ixazomib (Ixa), IV daratumumab (Dara), and dexamethasone (dex; IDd) in relapsed/refractory multiple myeloma (RRMM) patients (pts) with 1–3 prior therapies: phase 2 study interim analysis (IA).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S154, doi. 10.1016/S2152-2650(21)02337-5
- By:
- Publication type:
- Article
OAB-016: Treatment pathways for patients with multiple myeloma: a real-life study based on the French National Claim database from 2014 to 2019.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S10, doi. 10.1016/S2152-2650(21)02090-5
- By:
- Publication type:
- Article
IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 10, p. 686, doi. 10.1016/j.clml.2021.05.012
- By:
- Publication type:
- Article
MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S426, doi. 10.1016/S2152-2650(21)01952-2
- By:
- Publication type:
- Article
MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S427, doi. 10.1016/S2152-2650(21)01953-4
- By:
- Publication type:
- Article
Poster: MM-171: Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed or Refractory to Prior Alkylators: A Pooled Analysis of the O-12-M1 and HORIZON Studies.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S251, doi. 10.1016/S2152-2650(21)01575-5
- By:
- Publication type:
- Article
Poster: MM-186: HORIZON (OP-106): Melflufen Plus Dexamethasone in 55 Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD): Subgroup Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S250, doi. 10.1016/S2152-2650(21)01573-1
- By:
- Publication type:
- Article
Venetoclax as Targeted Therapy for Relapsed/Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e27, doi. 10.1016/j.clml.2017.03.046
- By:
- Publication type:
- Article
A Phase 1b Study of Venetoclax Combined with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e16, doi. 10.1016/j.clml.2017.03.027
- By:
- Publication type:
- Article
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00805-x
- By:
- Publication type:
- Article
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00803-z
- By:
- Publication type:
- Article
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
- Published in:
- 2023
- By:
- Publication type:
- Letter
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry.
- Published in:
- 2023
- By:
- Publication type:
- Letter
Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma.
- Published in:
- Frontiers in Physiology, 2017, v. 8, p. 1, doi. 10.3389/fphys.2017.00149
- By:
- Publication type:
- Article
Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.262884
- By:
- Publication type:
- Article
Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 257, doi. 10.2967/jnumed.121.262884
- By:
- Publication type:
- Article
Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.262884
- By:
- Publication type:
- Article
Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.121.262884
- By:
- Publication type:
- Article
Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.121.262884
- By:
- Publication type:
- Article
Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 3, p. 1, doi. 10.2967/jnumed.121.262884
- By:
- Publication type:
- Article
Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genomewide transcriptome analysis from the CASSIOPET study.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.262884
- By:
- Publication type:
- Article
Multiple myeloma mimicking metastatic skull base paraganglioma in [<sup>68</sup> Ga]Ga-DOTATOC-PET/CT and 2-[<sup>18</sup>F]FDG-PET/CT imaging.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 12, p. 3792, doi. 10.1007/s00259-023-06322-0
- By:
- Publication type:
- Article
Real‐life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study.
- Published in:
- EJHaem, 2024, v. 5, n. 1, p. 55, doi. 10.1002/jha2.828
- By:
- Publication type:
- Article
Anti‐SARS‐CoV‐2 vaccines in recipient and/or donor before allotransplant.
- Published in:
- EJHaem, 2022, v. 3, n. 2, p. 484, doi. 10.1002/jha2.398
- By:
- Publication type:
- Article
Extensive myelitis with eosinophilic meningitis after Chimeric antigen receptor T cells therapy.
- Published in:
- EJHaem, 2022, v. 3, n. 2, p. 533, doi. 10.1002/jha2.381
- By:
- Publication type:
- Article
Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients.
- Published in:
- EJHaem, 2021, v. 2, n. 3, p. 520, doi. 10.1002/jha2.242
- By:
- Publication type:
- Article
RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation.
- Published in:
- EJHaem, 2020, v. 1, n. 1, p. 1, doi. 10.1002/jha2.8
- By:
- Publication type:
- Article
A new cytokine‐based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 2, p. 642, doi. 10.1002/cam4.3648
- By:
- Publication type:
- Article
BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1196005
- By:
- Publication type:
- Article
Grade 2 acute GVHD is a factor of good prognosis in patients receiving peripheral blood stem cells haplo-transplant with post-transplant cyclophosphamide.
- Published in:
- Acta Oncologica, 2021, v. 60, n. 4, p. 466, doi. 10.1080/0284186X.2020.1837947
- By:
- Publication type:
- Article
Quad‐class exposed/refractory myeloma is associated with short survival.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 1, p. 186, doi. 10.1111/bjh.19148
- By:
- Publication type:
- Article
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 6, p. 988, doi. 10.1111/bjh.18233
- By:
- Publication type:
- Article
Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019.
- Published in:
- British Journal of Haematology, 2022, v. 197, n. 1, p. 82, doi. 10.1111/bjh.18025
- By:
- Publication type:
- Article
Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 5, p. e38, doi. 10.1111/bjh.17911
- By:
- Publication type:
- Article
Patient‐reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 3, p. 639, doi. 10.1111/bjh.17887
- By:
- Publication type:
- Article
Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 2, p. 360, doi. 10.1111/bjh.17818
- By:
- Publication type:
- Article